Eliminating Side Effects In Silico
Next-generation pain medications developed with computer simulations could improve on current opioid offerings
Roisin McGuigan |
“My group has studied the biology and pharmacology of opioid receptors on peripheral sensory neurons for over 25 years”, says Christoph Stein, Director, Department of Anesthesiology and Surgical Intensive Care Medicine, Charité – Universitätsmedizin Berlin. “Our aim has always been to find mechanisms and opioid receptor ligands that can be developed into drugs which inhibit pain, without also eliciting typical adverse effects of conventional opioids, such as apnea, addiction, sedation or constipation.”
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine